Precision therapy has long been hailed as the future of oncology, with medications becoming more targeted to specific mutations in tumors. However, a new player in the field, Dispatch Bio, is taking a different approach by aiming to develop a universal immunotherapy to treat any type of cancer.
At the core of Dispatch Bio’s strategy is the use of a synthetic protein known as the “flare” antigen. This protein is designed to be installed on every cancer cell within a patient’s body. Once in place, the company can then direct immunotherapies to target and eliminate the cancer cells carrying this protein, regardless of the type or location of the cancer.
Lex Johnson, the Chief Platform Officer at Dispatch, explained in a video on the company’s website that their approach differs from previous strategies that have focused on addressing specific diseases or problems. Dispatch’s universal approach is made possible by the engineering work done around the unique flare protein.
While the details of Dispatch Bio’s immunotherapy approach are still evolving, the potential implications of such a universal treatment are significant. By targeting a common protein found on all cancer cells, Dispatch’s therapy has the potential to revolutionize cancer treatment by offering a one-size-fits-all solution.
As the field of oncology continues to evolve, it will be interesting to see how Dispatch Bio’s universal immunotherapy approach fares in clinical trials and whether it will indeed pave the way for a new era in cancer treatment. With the promise of treating any type of cancer using a single therapy, Dispatch Bio’s innovative approach holds great promise for the future of oncology.
